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                                  This year it is estimated that 42    470 Americans will be diagnosed 
with pancreatic cancer and 35    240 will die from their disease (  1  ). 
Both environmental and genetic factors contribute to the etiology 
of pancreatic cancer (  2  ). Twenty percent of cases are attributable 
to cigarette smoking, the most important established risk factor 
(  3    –    5  ). Other important risk factors include a family history of pan-
creatic cancer, presence of type 2 diabetes mellitus, inherited and/
or long-standing chronic pancreatitis and obesity (  6    –    12  ). 
  Numerous case reports, case  –  control studies, and cohort 
studies have demonstrated that individuals with a family history of 
pancreatic cancer are at increased risk of developing pancreatic 
cancer themselves (  4  ,  8  ). The National Familial Pancreas Tumor 
Registry (NFPTR) was created in 1994 to understand better the 
genetic and environmental factors that cause the familial aggrega-
tion of pancreatic cancer. As of November 5, 2009, 3491 families 
had enrolled in the NFPTR. Of these, 1,146 families met the 
established deﬁ  nition of “familial pancreatic cancer (FPC)” because 
they had a pair of ﬁ  rst-degree relatives with pancreatic cancer. 
Families that do not meet this criterion (ie, families with only one 
relative with pancreatic cancer or with multiple pancreatic cancers 
in more distant relatives and/or spouses with pancreatic cancer) are 
deﬁ  ned as sporadic pancreatic cancer (SPC) kindreds. The goal of 
this classiﬁ  cation is to identify kindreds that harbor a pancreatic 
cancer susceptibility gene(s). 
  Previously, we demonstrated that members of FPC kindreds had 
an increased risk of developing pancreatic cancer and that this risk 
increased with the number of affected ﬁ  rst-degree relatives (  12  ,  13  ). 
Germline mutations in the   CDKN2A  ,   BRCA2  ,   PALB2  ,   STK11  , and 
  PRSS1   genes have been shown to increase a person  ’  s risk of devel-
oping pancreatic cancer (  10  ,  14    –    19  ); however, these known genetic 
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syndromes account for only 10%  –  20% of the familial clustering of 
pancreatic cancer. Pedigree studies support the existence of addi-
tional pancreatic cancer susceptibility genes (  20  ), and linkage studies 
to localize these susceptibility genes are currently under way (  21  ). 
  In addition to family history, some studies have suggested that 
relatives of young-onset pancreatic cancer patients may have a 
higher risk of developing pancreatic cancer even in the absence of 
multiple affected relatives (  22  ). In other cancer syndromes, in-
cluding hereditary breast and ovarian cancer syndrome and hered-
itary colon cancer, family members who carry the gene mutations 
associated with these syndromes develop cancer at a younger age 
than persons with sporadic cancers. For example, the Amsterdam 
Criteria (  23  ), which were created to identify individuals at high risk 
for germline mutations associated with hereditary nonpolyposis 
colorectal cancer, include, as a prominent criterion, having a 
family member diagnosed with colon cancer before the age of 
50 years. In addition, carriers of   BRCA1   and   BRCA2   gene muta-
tions are known to develop breast or ovarian cancers at a younger 
age than patients with sporadic breast or ovarian cancers (  24  ). 
  However, it is uncertain whether inherited pancreatic cancer is 
more likely than sporadic pancreatic cancer to follow a course of 
early-onset presentation. The average age of onset among the FPC 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  It was not clear whether family members of young-onset pancre-
atic cancer patients are at greater risk of developing pancreatic 
cancer than family members of older-onset patients.   
    Study design 
  Standardized incidence ratios for members of Familial Pancreatic 
Cancer (FPC) and Sporadic Pancreatic Cancer (SPC) families were 
calculated with data from the US National Familial Pancreas Tumor 
Registry compared with those from the Surveillance, Epidemiology, 
and End Results database. A statistical model that considered 
death due to other causes as a competing event was used to esti-
mate lifetime risk of pancreatic cancer among family members.   
    Contribution 
  Members of FPC families had a more than sixfold higher incidence 
of pancreatic cancer than the general population, and relatives of 
those patients diagnosed before the age of 50 years had a more 
than ninefold higher incidence of pancreatic cancer; members of 
SPC families, regardless of the age of onset of pancreatic cancer in 
their relative, had more than twofold higher incidence. In contrast 
to its elevation of risk among FPC family members, age of onset 
did not alter risk among sporadic pancreatic cancer family 
members.   
    Implications 
  Among families with a clustering pancreatic cancer, young-onset 
disease is associated with particularly high cancer risk.   
    Limitations 
  Some FPC family members underwent pancreatic cancer screening, 
which could have increased disease detection. Also, often data 
were obtained from a next of kin proxy, so only 66% of prospective 
cancers were confirmed by medical records. 
    From the Editors       
    
patients who were recruited as part of the Pancreatic Cancer 
Genetic Epidemiology Consortium (PacGENE) was approxi-
mately 6 years younger than the age of onset for pancreatic cancer 
in the general US population (around 70 years), although some of 
this difference may reﬂ  ect ascertainment bias because many partic-
ipants self-enrolled in high-risk family registries (  21  ). Additionally, 
segregation analysis provided evidence of a major gene for pancre-
atic cancer that inﬂ  uences age of onset, such that the mean age of 
onset of pancreatic cancer was estimated to be 72 years in gene 
carriers compared with 110 years in noncarriers (assuming no 
competing causes of death). However, other studies have demon-
strated that the average age of onset of pancreatic cancer is quite 
similar between FPC and SPC (nonfamilial) kindreds (  25  ). 
  To address the question of whether the incidence of pancreatic 
cancer is higher among individuals with a family history of young-
onset pancreatic cancer, we compared the incidence of pancreatic 
cancer among relatives of young- and late-onset pancreatic cancer 
patients enrolled in the NFPTR. Standardized incidence ratios 
(SIRs) were computed that compared the incidence of pancreatic 
cancer in these subgroups with that expected in Surveillance, 
Epidemiology, and End Results (SEER). Furthermore, competing 
risk survival analysis was conducted to estimate the risk of death due 
to pancreatic cancer and that due to other causes and to estimate 
whether age of onset of pancreatic cancer modiﬁ  ed these risks. 
    Subjects and Methods 
    Study Subjects 
  This study was reviewed and approved by the Institutional Review 
Board of the Johns Hopkins Medical Institutions, and informed 
consent was obtained from all study participants. NFPTR was 
established at The Johns Hopkins Hospital on January 1, 1994, 
and to our knowledge is currently one of the largest registries of 
pancreatic cancer kindreds. 
  Family members were eligible for the study if they did not have 
pancreatic cancer at the time of their enrollment in the NFPTR; if 
they enrolled between January 1, 1994, and December 31, 2006; 
and if any follow-up was available. FPC kindreds were deﬁ  ned as 
families with at least a pair of ﬁ  rst-degree relatives with ductal 
adenocarcinoma of the pancreas (ie, a parent  –  offspring or sibling 
pair). SPC kindreds were deﬁ  ned as those families which included 
a pancreatic cancer patient but did not include a pair of affected 
ﬁ  rst-degree relatives. Follow-up was available for at least one indi-
vidual from 72% of the families who had been enrolled in the 
NFPTR before December 31, 2006. 
  After written informed consent was obtained, a questionnaire 
was completed by either the pancreatic cancer patient (40%) or by 
a proxy of the patient (60%). The questionnaire included informa-
tion on the cancer history and smoking exposures of patients and 
their family members. This       information included age, sex, cancer 
status, age at cancer diagnosis, and ever vs never cigarette smoking 
status. At least one member of each family was contacted annually 
by mail to obtain updated health information, including vital status 
and cancer diagnoses for all members. Whenever possible, inci-
dent pancreatic cancers were conﬁ   rmed through requisition of 
pathology reports, review of pathology slides, medical records, 
and/or death certiﬁ  cates.   jnci.oxfordjournals.org    JNCI | Articles 121
    Statistical Methods 
  Standardized incidence ratios were calculated by comparing the 
number of incident pancreatic cancers observed in kindreds 
enrolled in the NFPTR with those expected using SEER incidence 
rates for the general population (  26  ). Person-years of follow-up 
were calculated from the time of enrollment in the NFPTR until 
the most recent contact date, date of pancreatic cancer diagnosis, 
date of death, or date of surgical resection of the pancreas. Total 
person-time in each stratum was multiplied by the age-, race-, sex-, 
and calendar year  –  specific SEER incidence rate to determine the 
expected incidence of pancreatic cancer. Young-onset pancreatic 
cancer kindreds were defined as kindreds in which a member had 
been diagnosed with pancreatic cancer before the age of 50 years, 
whereas late-onset kindreds were defined as kindreds in which all 
pancreatic cancers developed at age 50 years or greater. Smokers 
were defined as individuals reported to have smoked more than 
100 cigarettes in their lifetime, and nonsmokers as individuals who 
never smoked or smoked fewer than 100 cigarettes. Individuals    
  with missing smoking data were categorized independently. 
Confidence       intervals (CIs) were determined based on the Poisson 
distribution and   P   values obtained using the approach of Rothman 
and Boice (  27  ) as detailed in Breslow and Day (  28  ). 
  Fewer than 200 individuals enrolled in the NFPTR also partic-
ipate in the Cancer of the Pancreas Screening (CAPS) research 
protocol to screen for precancerous lesions in the pancreas. 
Because these individuals represented those at the highest risk of 
developing pancreatic cancer, exclusion of these patients would 
have caused an underestimation in risk. We therefore accounted 
for the impact of early detection (either clinical screening or 
screening as part of CAPS) by incorporating the effect of screening 
into the analysis as follows. Individuals who underwent pancreatec-
tomy based on the results of their screening examinations were 
censored at their date of surgery. Individuals whose resected pan-
creas was found to have one or more of the following histologies 
(after pathological evaluation of resected tissue by R. H. Hruban) 
were considered to have pancreatic cancer: invasive adenocarci-
noma (n = 0), pancreatic intraepithelial neoplasia-3 (PanIN-3) (n = 
2, including one patient with 14 PanIN-3 lesions and a focus of 
microinvasive carcinoma), or intraductal papillary mucinous neo-
plasm with high-grade dysplasia (n = 2). Given that these high-
grade precursor lesions are rarely observed in individuals without 
pancreatic cancer (  29  ), it is very likely that these patients would 
have developed pancreatic cancer during follow-up if they had 
been left untreated. The remaining nine individuals enrolled in 
CAPS who underwent partial or total pancreatectomies, but were 
found not to have one of these high-grade lesions, were considered 
free of pancreatic cancer at last follow-up. In addition, there was 
one individual who was found to have unresectable pancreatic can-
cer during screening and was considered affected in all analyses. 
  Time-to-event analyses were conducted using competing risk 
methods (  30    –    33  ). Brieﬂ  y, although individuals are at risk for pan-
creatic cancer, it is probable that some individuals will die from 
other causes before pancreatic cancer can occur. These       competing 
causes of death may be important, given that both known factors 
(ie, cigarette smoking, germline   BRCA2   mutations) and unknown 
genetic factors may be associated both with risk of pancreatic can-
cer and with mortality due to other causes (ie, other cancers, car-
diovascular disease). Because of these competing risks, the observed 
cumulative incidence of pancreatic cancer will be smaller. 
Therefore, a cause-speciﬁ  c proportional hazards model, in which 
youngest age of onset was treated as a continuous variable, was 
used to assess the association of the development of pancreatic 
cancer in study subjects with the age at onset of pancreatic cancer 
in a family member (  34  ,  35  ). The cause-speciﬁ  c model was essen-
tially a standard Cox proportional hazards model that jointly mod-
eled both the development of pancreatic cancer and all-cause 
mortality using the data augmentation approach that stratiﬁ  es the 
model on event type as outlined by Lunn and McNeil (  35  ). To 
estimate the cumulative incidence of pancreatic cancer in the pres-
ence of the competing risk of death, the cause-speciﬁ  c hazards for 
pancreatic cancer and the cause-speciﬁ  c hazards for all-cause mor-
tality from the joint proportional hazards model were combined 
(  36  ,  37  ):     11 2 00 () () e x p( ( () () ) ) ,    ³³
ts
CIF t h s h u h u du ds    where CIF      (  t  ) 
is the cumulative incidence function,   h    1   and   h    2   are the cause-
speciﬁ  c hazards for pancreatic cancer and all-cause mortality, re-
spectively. Modeling both events in a joint cause-speciﬁ  c hazards 
model makes it possible for the cumulative incidence function 
of pancreatic cancer in the presence of a competing event to be 
estimated (  31    –    33  ). 
  We used a robust grouped jackknife variance estimator to allow 
for correlation between family members (  38  ). Age was used as the 
time scale for the survival analyses. Because there was some indi-
cation that the proportional hazards assumption did not hold with 
all-cause mortality, a binary interaction with age (70 years) was 
included for the variables in which there was an indication of non-
proportionality. Nonlinear associations between covariates and 
events were examined using fractional polynomials (  39  ,  40  ) but 
were not found to improve the model ﬁ  t, and therefore, these were 
not included in the ﬁ  nal model. 
  Parameter estimates from the ﬁ  nal ﬁ  tted models were used to 
estimate the cumulative incidence pancreatic cancer in the pres-
ence of competing risks (  31    –    33  ). Variability of the cumulative 
incidence estimates was then obtained using bootstrapping (1500 
iterations) (  41  ). Iterations (n = 18) in which the model had conver-
gence problems because of small sample sizes were dropped. 
  All analyses were done in R version 2.7 (    http  ://  www  .  r  -  project  .
  org  /  ). All   P   values are two-sided.     
    Results 
  A total of 9040 individuals who had at least one first-degree rela-
tive with pancreatic cancer, from 1718 kindreds, were included in 
this study. They contributed to a total of 34    878 person-years of 
follow-up. A total of 41 study subjects developed prospective 
pancreatic cancers: 29 members of FPC kindreds, eight members 
of SPC kindreds, and four participants who were genetically un-
related to the probands in their families (  Table 1  ). Twenty-seven 
(66%) of the 41 prospective pancreatic cancers included in this 
study were confirmed by review of pathology reports, micro-
scopic slides, and/or death certificates. In addition to the 41 
prospective pancreatic cancers included in the analyses, 22 pro-
spective pancreatic cancers developed in either more distant 
(non  –  first-degree) relatives (n = 13) or after the follow-up period 
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  We compared the incidence of pancreatic cancer in the NFPTR 
with that expected from SEER data (  Table 2  ). When we controlled 
for age, race, sex, and calendar year, the overall observed incidence 
of pancreatic cancer in the FPC kindreds was higher than that 
expected in the general population from SEER data (FPC SIR = 
6.79, 95% CI = 4.54 to 9.75,   P   < .001).         
  In the FPC kindreds, risk varied by the number of ﬁ  rst-degree 
relatives with pancreatic cancer, such that risk was higher in indi-
viduals with three ﬁ  rst-degree relatives who had pancreatic cancer 
(SIR = 17.02, 95% CI = 7.34 to 33.5,   P   < .001) but lower in indi-
viduals who had two ﬁ  rst-degree relatives with pancreatic cancer 
(SIR = 3.97; 95% CI = 1.59 to 8.2,   P   = .005) or with one affected 
ﬁ  rst-degree relative (SIR = 6.86, 95% CI = 3.75 to 11.04,   P   < .001). 
Whereas risk was higher for FPC kindred members who had one 
ﬁ  rst-degree relative with pancreatic cancer as compared with two, 
the conﬁ  dence intervals for these two estimates largely overlap. 
  The observed incidence of pancreatic cancer in the SPC kin-
dreds was also statistically signiﬁ  cantly higher than that expected 
from SEER data (SPC SIR = 2.41, 95% CI 1.04 to 4.74,   P   = .04). 
Risk among unrelated individuals (spouses) was also elevated (un-
related SIR = 2.14, 95% CI = 0.58 to 5.49,   P   = .23), but this 
increase was not statistically signiﬁ   cant. Because spouses share 
environmental but not genetic factors with the at-risk relatives, we 
included this population as an internal control group. 
  Table 1    .       Demographics of study population  *     
    Subject group
Family members at risk   
Incident pancreatic cancers among 
family members     
  No. of individuals
Mean age at 
baseline (±SD) No. of individuals
Mean age at diagnosis of 
pancreatic cancer (±SD)   
    Subjects from FPC kindreds 
         Men 1841 55.6 (±17.8) 10 67.7 (±8.9) 
         Women 2093 57.9 (±18.4) 19 68.9 (±12.4) 
  Subjects from SPC kindreds 
         Men 1856 55.1 (±17.8) 2 73.6    †     
         Women 2160 57.5 (±18.4) 6 73.9 (±11.5) 
  Genetically unrelated subjects 
         Men 448 70.8 (±11.6) 2 81.1    †     
         Women 642 67.6 (±12.1) 2 76.1    †     
  Total 9040 58.1 (±18.0) 41 69.7 (±10.9)   
    *     Genetically unrelated subjects are spouses and non-blood relatives associated with either FPC or SPC kindreds. Study population is from the Johns Hopkins 
University National Familial Pancreas Tumor Registry database. FPC = familial pancreatic cancer; SPC = sporadic pancreatic cancer.   
      †       SDs are not presented because of small number of individuals.     
  Table 2    .       Standardized incidence ratios (SIRs) of pancreatic cancer among family members at risk: overall and stratified by family 
history and smoking status  *     
    Family history No. of individuals
Person-years of 
follow-up
Observed 
cases
Expected 
cases SIR  *   (95% CI)   P     
    Familial 
         Overall 3934 16    760 29 4.27 6.79 (4.54 to 9.75) <.001 
         Three or more first-degree relatives 176 797 8 0.47 17.02 (7.34 to 33.5) <.001 
         Two first-degree relatives 1043 4477 7 1.76 3.97 (1.59 to 8.2) .005 
         One first-degree relatives 2715 11    486 14 2.04 6.86 (3.75 to 11.04) <.001 
         Young-onset kindred 705 3093 6 0.64 9.31 (3.42 to 20.28) <.001 
         Late-onset kindred 3229 13    666 23 3.63 6.34 (4.02 to 9.51) <.001 
         Smokers 1399 6125 14 1.54 9.09 (4.97 to 15.25) <.001 
         Nonsmokers 2009 8553 12 1.88 6.38 (3.02 to 11.15) <.001 
         Unknown smoking history 526 2083 3 0.85 3.53 (0.73 to 10.32) .112 
  Sporadic 
         Overall 4015 13    876 8 3.32 2.41 (1.04 to 4.74) .04 
         Young-onset kindred 472 1695 1 0.36 2.74 (0.05 to 15.30) .59 
         Late-onset kindred 3544 12    181 7 2.96 2.36 (0.95 to 4.88) .06 
         Smokers 1377 4681 4 1.31 3.04 (0.83 to 7.79) .09 
         Nonsmokers 2096 7215 3 1.39 2.15 (0.45 to 8.98) .32 
         Unknown smoking history 542 1979 1 0.62 1.61 (0.04 to 8.93) .91 
  Unrelated 
         Overall 1091 4240 4 1.86 2.14 (0.58 to 5.49) .23 
         Smokers 434 1407 2 0.67 2.98 (0.37 to 10.77) .28 
         Nonsmokers 434 1619 2 0.65 3.07 (0.37 to 11.11) .27 
         Unknown smoking history 223 1213 0 0.55 0 (0 to 6.71) .94   
    *     Age-, sex-, race-, and calendar year  –  specific standardized incidence ratios were computed compared with data from the Surveillance, Epidemiology, 
and End Results database.     jnci.oxfordjournals.org    JNCI | Articles 123
  To understand the effect of having a young-onset pancreatic 
cancer in the family on an individual’s risk of developing pancre-
atic cancer, families were stratiﬁ   ed into young- and late-onset 
kindreds (  Table 2  ). We deﬁ   ned young-onset pancreatic cancer 
families as those in which there was at least one family member 
who was diagnosed with pancreatic cancer before the age of 
50 years. Our data suggest that individuals from familial pancreatic 
kindreds in which at least one family member was diagnosed 
younger than 50 years are at higher risk of developing pancreatic 
cancer than individuals from FPC kindreds without a young-onset 
pancreatic cancer (FPC young-onset SIR = 9.31, 95% CI = 3.42 to 
20.28,   P   < .001; FPC late-onset SIR = 6.34, 95% CI = 4.20 to 9.51, 
  P   < .001). A similar difference in pancreatic cancer risk between 
families with and without a young-onset cancer patient was not 
seen among the SPC kindreds (SPC young-onset SIR = 2.74, 
95% CI = 0.05 to 15.30,   P   = .59; SPC late-onset SIR = 2.36, 
95% CI = 0.95 to 4.88,   P   = .06). 
  To estimate the lifetime risk of pancreatic cancer in the FPC 
and SPC kindreds, we conducted time-to-event (pancreatic can-
cer) analyses using Cox proportional hazards modeling that con-
sidered deaths due to other causes as competing events (  Table 3  ). 
It is important to note that the hazard ratio (HR) estimates 
obtained in these models do not directly estimate the cumulative 
incidence because the cause-speciﬁ  c hazard ratio only assesses the 
instantaneous risk of that event without considering the cumula-
tive effect of the competing event (  36  ,  37  ). Therefore, in   Figure 1  , 
we provide the cumulative risk estimates for pancreatic cancer as 
well as risk of death due to other causes derived from the propor-
tional hazards modeling.                 
  In the FPC kindreds, the hazard of pancreatic cancer increased 
as the age of the youngest proband decreased (HR = 1.55 per year 
of decreased age of the proband, 95% CI = 1.19 to 2.03). Risk was 
also statistically signiﬁ  cantly higher among FPC kindred members 
with three ﬁ  rst-degree relatives with pancreatic cancer compared 
with those with a single ﬁ  rst-degree relative with pancreatic cancer 
(HR = 2.95, 95% CI = 1.24 to 7.04). 
  Whereas data for time to pancreatic cancer were not substan-
tially different for men compared with women and for cigarette 
smokers compared with nonsmokers, men (HR = 1.36, 95% CI = 
0.97 to 1.92,   P   = .07), and ever-smokers (HR = 1.47, 95% CI = 0.96 
to 2.25,   P   = .07), the FPC kindreds had an increased hazard of 
death due to causes other than pancreatic cancer, although these 
differences were not statistically signiﬁ  cant. 
  Using these models adjusted for effects smoking and gender on 
all-cause mortality, we estimated the lifetime risk of pancreatic 
cancer and the risk of death due to other causes (  Figure 1  ). The 
cause-speciﬁ  c proportional hazards model suggested that the cu-
mulative incidence of pancreatic cancer by age 80 years was 15.7% 
(95% bootstrap CI = 8.5% to 23.7%) among FPC kindred mem-
bers who had either one or two ﬁ  rst-degree relatives with pancre-
atic cancer and at least one relative whose disease onset was at 40 
years of age. In this family history group, the cumulative incidence 
of pancreatic cancer decreased to 7.1% (95% CI = 3.6% to 10.7%) 
when the youngest age of onset of pancreatic cancer was at 60 
years and to 3.1% (95% CI = 0.9% to 6.9%) when the youngest 
age was at 80 years. 
  The cumulative incidence of pancreatic cancer by age 80 years 
was 38.5% (95% bootstrap CI = 13.1% to 64.3%) among FPC 
kindred members with three ﬁ  rst-degree relatives with pancreatic 
cancer and at least one relative whose disease onset was at 40 years 
of age. The cumulative incidence of pancreatic cancer decreased to 
19.2% (95% CI = 6.1% to 34.3%) for FPC kindred members when 
the youngest age of onset of pancreatic cancer was at 60 years and 
to 8.7% (95% CI = 1.9% to 21.4%) when the youngest age was at 
80 years. 
  In SPC kindreds, time to pancreatic cancer did not vary by 
proband age of onset (HR = 0.99, 95% CI = 0.59 to 1.66,   P   = .99) 
(  Table 3  ). Additionally, there was an interaction between age and 
smoking such that smokers older than 70 years had a hazard ratio 
for death of 1.05 (95% CI = 0.66 to 1.68,   P   = .83) compared with 
nonsmokers, whereas smokers younger than 70 years had a hazard 
ratio for death of 3.22 (95% CI = 1.22 to 8.54,   P   = .019) compared 
  Table 3    .       Cause-specific hazard ratio (HR) models        *     
    Characteristics of individuals
Pancreatic cancer, 
HR    †     (95% CI)   P 
Death from other causes, 
HR (95% CI)   P     
    Familial 
         Youngest age of onset in relative 
      (per year younger)
1.55 (1.19 to 2.03) .001 1.09 (0.90 to 1.32) .38 
         Three or more first-degree relatives 2.95 (1.24 to 7.04) .015   —  
         Ever-smoker   —    1.47 (0.96 to 2.25) .075 
         Unknown smoking history   —    1.09 (0.64 to 1.87) .076 
         Male   —    1.36 (0.97 to 1.92) .079 
  Sporadic 
         Youngest age of onset 0.99 (0.59 to 1.66) .99 0.95 (0.80 to 1.14) .61 
         Ever-smoker, age <70 y   —    3.22 (1.22 to 8.54) .019 
         Ever-smoker, age >70 y   —    1.05 (0.66 to 1.68) .83 
         Unknown smoking history, age <70 y   —    6.32 (1.30 to 30.70) .02 
         Unknown smoking history, age >70 y   —    1.54 (0.91 to 2.61) .11 
         Male, age <70 y   —    0.93 (0.46 to 1.88) .83 
         Male, age >70 y   —    1.69 (1.14 to 2.50) .01   
    *     The HRs were estimated from a Cox proportional hazards model in which the competing event is treated as censored. These models cannot be interpreted in 
the same manner as a standard proportional hazards model without a competing event (see text). CI = confidence interval.   
      †       The inferences regarding youngest age of onset were not changed by including smoking status and sex. Therefore, the reduced model is presented as the 
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with nonsmokers (  Table 3  ). In the sporadic kindreds, men older 
than 70 years had an increased hazard of death due to causes other 
than pancreatic cancer compared with women (HR = 1.69, 95% 
CI = 1.14 to 2.50,   P   = .01), whereas risk of death due to other 
causes was similar in men and women younger than 70 years (HR = 
0.927, 95% CI = 0.46 to 1.88,   P   = .83) (  Table 3  ). The cumulative 
incidence of pancreatic cancer by age 80 years was 3.3% (95% 
CI = <0.1% to 5.9%) among sporadic kindred members at the 
median youngest age of onset in the kindred of 62 years (  Figure 1  ). 
Given the limited number of incident pancreatic cancers that 
developed in individuals not genetically related to the proband 
(n = 4), accurate estimation of the cumulative risk of pancreatic 
cancer in the unrelated individuals was not possible.   
    Discussion 
  A family history of pancreatic cancer is one of the strongest risk 
factors for the development of pancreatic cancer. Our results indi-
cate that individuals from familial pancreatic kindreds in which at 
least one member of the family had been diagnosed with pancreatic 
cancer at a young age had a statistically significantly increased risk 
of developing pancreatic cancer themselves. The lifetime risk of 
pancreatic cancer was higher when there was an early-onset pan-
creatic cancer in the family, and this risk decreased as the youngest 
age of onset in the family increased. The lifetime (by age 80 years) 
risk of pancreatic cancer was 15.7% for individuals with one or two 
first-degree relatives with pancreatic cancer who came from a 
family in which one of the members of the family was diagnosed 
at age of 40 years. This lifetime risk rose to 38.9% (  Figure 1  ) for 
individuals with three first-degree relatives with pancreatic cancer 
who came from a family in which one of the members of the family 
was diagnosed at age 40 years. By contrast, individuals from fam-
ilies who had either one or two first-degree relatives with late-
onset pancreatic cancer (at age 80 years) had a cumulative incidence 
risk of pancreatic cancer that was the same as the risk in individuals 
from SPC kindreds (2.9 and 3.3 by age 80 years, respectively). This 
trend is similar to that which is observed in other cancers, such as 
breast, ovarian, and colon cancers (  23    –    25  ). 
  Understanding the inﬂ  uence of family history and age of onset 
of pancreatic cancer on the lifetime risk of pancreatic cancer will 
help to inform the clinical counseling and screening of high-risk 
families. Current screening strategies for pancreatic cancer are 
directed at those who are most at risk. For example, the inclusion 
criteria for the ongoing CAPS trial (  42  ,  43  ) include family history 
  Figure 1    .       Cumulative       risk of pancreatic cancer among members of pan-
creatic cancer families compared with cumulative risk of death from 
other causes.   A  ) Cumulative risk of pancreatic cancer among members 
of familial pancreatic cancer (FPC) kindreds who have one or two ﬁ  rst-
degree relatives with pancreatic cancer.   B  ) Cumulative risk of death due 
to other causes in FPC kindred members as in (  A  ).   C  ) Cumulative risk of 
pancreatic cancer in FPC kindred members with three or more ﬁ  rst-
degree relatives with pancreatic cancer.   D  ) Cumulative risk of death due 
to other causes in FPC kindred members as in (  C  ). In all panels,   solid and 
dashed lines   reﬂ  ect cumulative risk in FPC kindreds by youngest age of 
onset of pancreatic cancer: age 40, 50, 60, 70, 80, and 90 years from top 
to bottom.   Shaded area   reﬂ  ects risk in sporadic kindred members.       jnci.oxfordjournals.org    JNCI | Articles 125
of pancreatic cancer and gene mutation status (  BRCA2  ,   STK11  , 
  CDKN2A  ), but they do not include age at which the pancreatic 
cancers were diagnosed in the family. The results of the current 
analyses should help guide this and other screening trials by sug-
gesting that the age of onset of the pancreatic cancers in a kindred 
be included among the eligibility criteria. 
  Moreover, the ﬁ  ndings we present will help to guide future can-
cer risk counseling to individuals even in the absence of an identi-
ﬁ  ed gene or genes. Better quantiﬁ  cation of risk can help alleviate 
the psychological stress of the unknown for individuals who have 
lost one or more loved ones to pancreatic cancer. For example, if the 
earliest age at which a member of a kindred developed onset of 
pancreatic cancer was older than 80 years, our data suggest that 
individuals in that kindred are at low risk. Our aggregate risk esti-
mates, based on the observed incidence of pancreatic cancer in our 
family cohort, can help to direct at-risk individuals to counseling 
and early detection trials, especially when used in connection with 
our recently developed and validated risk prediction model 
PancPRO, which provides individual-level risk assessment (  44  ). By 
using full pedigree data (age, pancreatic cancer status, age of onset, 
and relationship for all biological relatives), PancPRO estimates an 
individual’s probability of carrying a pancreatic cancer susceptibility 
gene and their lifetime risk of developing pancreatic cancer (  44  ). 
  This study is the ﬁ  rst to our knowledge to examine the inﬂ  uence 
of age of onset on the prospective risk of pancreatic cancer in high-
risk families. Strengths of our study include the large sample of FPC 
and SPC patients, extensive follow-up, and the use of only prospec-
tive data. Our large sample of both FPC and SPC kindreds allows 
us to compare directly the inﬂ  uence of age at onset in these two 
groups. Furthermore, our use of prospective data limits recall bias. 
  One potential limitation to our study is that some patients 
underwent early detection screening for pancreatic cancer, in-
cluding 13 individuals who had a surgical resection of their pan-
creas based on the results of screening. However, because screening 
of high-risk individuals is becoming more common, this limitation 
is common to many prospective studies of pancreatic cancer kin-
dreds. We accounted for the screened individuals in the risk-set. 
Only screened individuals who underwent surgical resection and 
were found to have high-grade precursor lesions (n = 4), that is, 
precursors rarely found in individuals without invasive pancreatic 
cancer (  29  ), were considered as “affected,” given the very high 
probability these lesions would develop into invasive cancer within 
a few years if not removed surgically. Aside from the single patient 
who developed pancreatic cancer while under screening, all other 
screened individuals, including nine patients who underwent sur-
gical resection and were found to have lower grade precursor le-
sions, were considered as free of pancreatic cancer at the end of 
follow-up. We conducted sensitivity analysis to examine the 
impact of this assumption by conducting analysis treating these 
four individuals with high-grade precursor lesions as “unaffected,” 
and while the point estimates were lower, the tests of hypothesis 
and inferences were consistent. 
  We were able to verify 66% of our prospective cancers. In most 
of the unconﬁ  rmed cases, we were not able to conﬁ  rm the diagno-
sis because we were not able to obtain permission from the patient 
or their next of kin because of the high mortality rate of this 
disease. When we examined data for the entire registry, in the 
cases where permission and records were obtained, more than 92% 
of the pancreatic cancers were conﬁ  rmed. Furthermore, because 
at-risk individuals do not typically have medical record conﬁ  rma-
tion of their relatives  ’   cancer when presenting to clinicians seeking 
screening, our results should be generalizable to those seeking 
screening for their risk of pancreatic cancer. Another potential 
limitation to our study is that 60% of our questionnaire data were 
obtained from a next of kin proxy, not the patient themselves. 
However, given that our data suggest that NFPTR reported family 
history of pancreatic cancer is highly accurate (  ~  92% sensitivity), 
and that lifetime smoking patterns have previously been shown to 
be highly accurate when reported by proxy (  45  ), we believe that 
any bias because of the use of proxy data is minimal. 
  In summary, in this study, we expanded upon our previous 
study of the prospective risk of developing pancreatic cancer by 
examining whether being related to an individual who developed 
pancreatic cancer at a young age is predictive of an increased risk 
of disease. These data should help to further inform risk assess-
ment and subsequent early detection screening of individuals at 
high risk of developing pancreatic cancer.   
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